

P/1259-637

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Date: April 28, 2006

Fernand LABRIE

Confirmation No.: 3989

Serial No.:

10/052,803

Group Art Unit: 1617

Filed:

November 7, 2001

Examiner: Shaojia A. Jiang

For:

SELECTIVE ESTROGEN RECEPTOR MODULATORS IN

COMBINATION WITH ESTROGENS

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT UNDER RULE 37 C.F.R. § 1.116

Sir:

This is a response to the Office Action in the above-identified application.

Reconsideration of the application is respectfully requested.

FEE CALCULATION

No additional fee is required.

	NO. CLAIMS AFTER		HIGHEST NO. PREVIOUSLY						A	ADDIT.	
<u>AMENDMENT</u>			PAID FOR	EXTRA PRESEN			NT_	NT RATE		FEE	
TOTAL	. 20	MINUS	43	* =		0	X	(\$25 SE or \$50)	<u>\$0</u>		
INDEP.	1	MINUS	. 4	** =		0	X	(\$100 SE or \$200)	\$0		
FIRST I	PRESENTATIO	OF MU	LTIPLE DEPE	NDENT	CLAIM		Х	(\$180 SE or \$360)	\$		
* not less than 20 ** not less than 3								TOTAL \$0			
	If any addition	nal payn	nent is require	ed, a ch	neck wh	ich	inclu	des the calculated	fee of	f <u>\$</u>	
(OEGS	Check No	١,	attached								

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Currently amended) A pharmaceutical composition comprising:

- a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one estrogen or prodrug thereof, said estrogen being selected from the group consisting of 17β -estradiol, 17β -estradiol esters, estriol, estriol esters, estrone, estrone esters, conjugated estrogen, equilin, equilin esters, 17α -ethynylestradiol, 17α -ethynylestradiol esters, mestranol, mestranol esters, chemestrogen, diethylstilbestrol, phytestrogen, tibolone, 2'-ethylestrogenoxazole, and ethynediol; and
 - c) a therapeutically effective amount of at least one selective estrogen receptor modulator or prodrug thereof, wherein the selective estrogen receptor modulator has the following formula:

OK TO ENTER! 5/7/06 YC

$$R_1$$
 G_3
 R_{100}
 R_{100}
 G_2

wherein R_1 and R_2 are independently hydrogen, hydroxyl or a moiety which is converted to hydroxyl in vivo;

wherein Z is either absent or selected from the group consisting of $-CH_2$ -,-0-,-S- and $-NR_3$ - (R_3 being hydrogen or lower alkyl);